Innovent Biologics Cash And Equivalents vs. Operating Margin
| IVBXF Stock | USD 4.86 0.03 0.62% |
For Innovent Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Innovent Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Innovent Biologics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Innovent Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Innovent Biologics over time as well as its relative position and ranking within its peers.
Innovent |
Innovent Biologics Operating Margin vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Innovent Biologics's current stock value. Our valuation model uses many indicators to compare Innovent Biologics value to that of its competitors to determine the firm's financial worth. Innovent Biologics is currently regarded as number one stock in cash and equivalents category among its peers. It is rated below average in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innovent Biologics' earnings, one of the primary drivers of an investment's value.Innovent Operating Margin vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Innovent Biologics |
| = | 8.32 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Innovent Biologics |
| = | (0.78) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Innovent Operating Margin Comparison
Innovent Biologics is currently under evaluation in operating margin category among its peers.
Innovent Biologics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Innovent Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Innovent Biologics will eventually generate negative long term returns. The profitability progress is the general direction of Innovent Biologics' change in net profit over the period of time. It can combine multiple indicators of Innovent Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people.
Innovent Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Innovent Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Innovent Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Innovent Biologics' important profitability drivers and their relationship over time.
Use Innovent Biologics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Innovent Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innovent Biologics will appreciate offsetting losses from the drop in the long position's value.Innovent Biologics Pair Trading
Innovent Biologics Pair Trading Analysis
The ability to find closely correlated positions to Innovent Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Innovent Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Innovent Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Innovent Biologics to buy it.
The correlation of Innovent Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Innovent Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Innovent Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Innovent Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Innovent Biologics position
In addition to having Innovent Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Services Thematic Idea Now
Services
Companies involved in delivering services to business or consumers across different industries and sectors. The Services theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Services Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Innovent Pink Sheet
To fully project Innovent Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Innovent Biologics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Innovent Biologics' income statement, its balance sheet, and the statement of cash flows.